A-1331852

Catalog No.S7801 Batch:S780104

Print

Technical Data

Formula

C38H38N6O3S
Molecular Weight 658.81 CAS No. 1430844-80-6
Solubility (25°C)* In vitro DMSO 100 mg/mL (151.78 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
2.5mg/ml Taking the 1 mL working solution as an example, add 50 μL of 50 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description A-1331852 is a potent and selectiveBCL-XL inhibitor with Ki value less than 0.01 nM for BCL-XL and 6 nM, 4 nM, 142 nM for Bcl-2, Bcl-W, MCL-1 respectively. It may be useful in the treatment of cancer, immune and autoimmune diseases.
Targets
Bcl-xL [1]
(Cell-free assay)
<0.01 nM(Ki)
In vitro A-1331852 exhibits remarkable potency both as a single agent and in combination with TKIs in killing primary CD34+ CML cell. Also, It has remarkable potency in inducing apoptosis in these cells at low nanomolar concentrations as early as 1 h post-treatment[2].
In vivo A-1331852 demonstrates antitumor efficacy in the Molt-4 xenograft model, inducing tumor regressions as a single agent[1].

Protocol (from reference)

Cell Assay:[2]
  • Cell lines

    K562 cells

  • Concentrations

    100 nM

  • Incubation Time

    0-2 h

  • Method

    Immunoprecipitation of BCL-XL is carried out in K562 cells, exposed to A-1331852 (100 nM) for 0-2 h, and the eluted complexes are immunoblotted for the indicated proteins. The input cell lysates and the immunodepleted supernatant (labeled as Flow-through) are immunoblotted to check the efficiency of the immunoprecipitation.

Animal Study:[1]
  • Animal Models

    SCID and SCID-bg mice

  • Dosages

    25 mg/kg

  • Administration

    Oral administration

Customer Product Validation

Data from [Data independently produced by , , Cancer Lett, 2018, 412:131-142]

Data from [Data independently produced by , , Mol Cancer Res, 2016, 14(12):1176-1181]

Selleck's A-1331852 has been cited by 50 publications

Gravitational and mechanical forces drive mitochondrial translation [ bioRxiv, 2024, 10.1101/2023.01.18.524628] PubMed: none
Clearance of defective muscle stem cells by senolytics restores myogenesis in myotonic dystrophy type 1 [ Nat Commun, 2023, 14(1):4033] PubMed: 37468473
Single-molecule fingerprinting of protein-drug interaction using a funneled biological nanopore [ Nat Commun, 2023, 14(1):1461] PubMed: 37015934
Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma [ Br J Cancer, 2023, 10.1038/s41416-023-02430-8] PubMed: 37723317
ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression [ Front Immunol, 2023, 14:1196731] PubMed: 37539056
Bcl-xL is required to protect endothelial cells latently infected with KSHV from virus induced intrinsic apoptosis [ PLoS Pathog, 2023, 19(5):e1011385] PubMed: 37163552
Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma [ iScience, 2023, 26(8):107369] PubMed: 37539026
Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors [ bioRxiv, 2023, 2023.08.01.551480] PubMed: 37577538
Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors [ bioRxiv, 2023, 2023.08.01.551480] PubMed: 37577538
Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer [ Nat Commun, 2022, 13(1):1199] PubMed: 35256598

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.